Visit MARGENZA Access Support to view financial support options and forms for patients, our network of authorized distributors, and information about coding, reimbursement, and claims.
Healthcare providers and prescribers can call 1-844-MED-MGNX to speak with a MARGENZA Access Support specialist who can assist with:
Download the Copay Assistance Enrollment Form, Patient Assistance Program Enrollment Form, and Billing and Coding Guide at MARGENZA Access Support.
Download for information that can help patients and caregivers better understand what to expect from MARGENZA, including treatment benefits, how it works, how it’s given, and more.Download
Download for National Drug Codes and additional quick reference information.Download
View efficacy and safety results
in the SOPHIA publication.
*NCCN makes no warranties of any kind whatsoever regarding their content, use, or application, and disclaims any responsibility for the application or use in any way.
MacroGenics does not recommend the use of one authorized distributor over another. MacroGenics does not make any warranty as to the services offered by any particular authorized distributor.
MacroGenics, the maker of MARGENZA,
proudly supports the HER2+
metastatic breast cancer community
WARNING: LEFT VENTRICULAR DYSFUNCTION AND EMBRYO-FETAL TOXICITY
The most common adverse drug reactions (>10%) with MARGENZA in combination with chemotherapy are fatigue/asthenia (57%), nausea (33%), diarrhea (25%), vomiting (21%), constipation (19%), headache (19%), pyrexia (19%), alopecia (18%), abdominal pain (17%), peripheral neuropathy (16%), arthralgia/myalgia (14%), cough (14%), decreased appetite (14%), dyspnea (13%), infusion-related reactions (13%), palmar-plantar erythrodysesthesia (13%), and extremity pain (11%).
MARGENZA is a HER2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.
Please see full Prescribing Information, including Boxed Warning.
You are about to go to a website that is operated by an independent third party. Your activities on the external website will be managed by its policies and practices. By clicking “Continue,” you will go to the external website.